Nanosphere Inc (NSPH) 0.59 $NSPH
Stock to Watch: Nanosphere Up 5.9% (NSPH)
Comtex SmarTrend(R) - Mon Sep 08, 10:38AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's best performing penny stocks, up 5.9% to $0.59 on 2.8x average daily volume. Nanosphere has traded 2.3 million shares thus far today, vs. average volume of 803,000 shares per day. The stock has outperformed the Dow (5.9% to the Dow's -0.1%) and outperformed the S&P 500 (5.9% to the S&P's -0.1%) during today's trading.
New Outcomes Data Presented at ICAAC 2014 Further Validates Clinical and Economic Utility of Nanosphere's Verigene Blood Culture Test
GlobeNewswire - Mon Sep 08, 7:06AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, announced that data from three outcomes studies demonstrating the clinical and economic impact of the Verigene(R) Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) for rapid sepsis diagnostic testing were presented yesterday at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in Washington, DC this week.
Nanosphere (NSPH) Slumps: NSPH Plunges 14.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:33AM CDT
Nanosphere, Inc. (NSPH) saw a big move last session,continuing the recent downtrend for NSPH, as the stock is now down 54.2% in the past one-month time frame.
VXZ, SPPRO, DLA, NSPH, USL, TITN Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Sep 05, 3:35AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of IPATH S&P 500 VIX M/T FU ETN (NYSE:VXZ), Supertel Hospitality Inc (NASDAQ:SPPRO), Delta Apparel Inc (NYSE
LA), Nanosphere Inc (NASDAQ:NSPH), United States 12 Month Oil Fund LP (NYSE:USL), Titan Machinery Inc (NASDAQ:TITN) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Nanosphere Announces Review of Strategic Alternatives
GlobeNewswire - Thu Sep 04, 3:01PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that the Company has engaged Jefferies LLC as its financial advisor to assist it in the development and evaluation of a full range of potential strategic alternatives for the Company.
Investors look to Lighten Up on Shares of Nanosphere, Shares Down 9.2% (NSPH)
Comtex SmarTrend(R) - Thu Sep 04, 10:38AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's worst performing penny stocks, down 9.2% to $0.69 on 1.3x average daily volume. Thus far today, Nanosphere has traded 912,000 shares, vs. average volume of 715,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's 0.3%) and underperformed the S&P 500 (-8.8% to the S&P's 0.3%) during today's trading.
New Clinical and Economic Outcome Data for Verigene Blood Culture Test to Be Presented at ICAAC 2014
GlobeNewswire - Tue Sep 02, 7:00AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that three outcomes studies demonstrating the clinical and economic impact of the Verigene(R) Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) will be presented at the 54 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held in Washington, DC on September 5 - 9, 2014.
Nanosphere Appoints Kristopher Wood to Its Board of Directors
GlobeNewswire - Wed Aug 20, 3:01PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced the appointment of Kristopher Wood to its board of directors. Mr. Wood brings to Nanosphere extensive experience in finance, strategy and venture capital.
Expert Briefing on Biotech Stocks -- Nanosphere, Vanda Pharma, Synta Pharma, Halozyme Therapeutics, and Isis Pharma
PR Newswire - Thu Aug 14, 8:30AM CDT
On Wednesday, August 13, 2014, the NASDAQ Composite ended at 4,434.13, up 1.02%, the Dow Jones Industrial Average finished the day 0.55% higher at 16,651.80, and the S&P 500 closed at 1,946.72, up 0.67%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.08, up 1.15%, with the index also advancing 4.55% in the previous three months. Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at:
Downgrade Alert for Nanosphere (NSPH)
Comtex SmarTrend(R) - Fri Aug 08, 7:08AM CDT
Nanosphere (NASDAQ:NSPH) was downgraded from Buy to Hold at Craig-Hallum today. The stock closed yesterday at $0.95 on volume of 4.9 million shares, above average daily volume of 1.2 million. Nanosphere Inc. develops, manufactures and markets an advanced molecular diagnostics platform. The Company's system allows highly sensitive genomic and protein testing on a single platform.
Why Nanosphere (NSPH) Stock Hit a One-Year Low Today
at The Street - Thu Aug 07, 12:12PM CDT
Nanosphere (NSPH) plummeted to a 52-week low of 92 cents on Thursday after the company reported second-quarter earnings and issued full-year revenue guidance that came up short of analysts' expectations.
Stock to Watch: Nanosphere Down 30.3% (NSPH)
Comtex SmarTrend(R) - Thu Aug 07, 10:11AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's worst performing penny stocks, down 30.3% to $0.99 on 1.8x average daily volume. Nanosphere has traded 2.6 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has underperformed the Dow (-30.3% to the Dow's -0.0%) and underperformed the S&P 500 (-30.3% to the S&P's 0.0%) during today's trading.
Nanosphere Announces Second Quarter Financial and Operating Results
GlobeNewswire - Wed Aug 06, 3:03PM CDT
Corporate Highlights and Business Guidance:
HemoSonics Names William P. Moffitt as Chairman of the Board of Managers
PR Newswire - Thu Jul 31, 9:23AM CDT
HemoSonics, a medical device company developing a novel point-of-care diagnostic to measure coagulation, announced today that William P. (Bill) Moffitt joined the Company as the new Chairman of the Board of Managers. Moffitt has 40 years of experience in the medical device and diagnostic industries and has spent the last 25 years developing novel technologies into products and solutions that have helped shape the industry.
Nanosphere to Release Second Quarter Results and Host Investor Conference Call on Wednesday, August 6, 2014
GlobeNewswire - Wed Jul 23, 7:26AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it will report its results for the second quarter of 2014 on Wednesday, August 6, 2014. The company will also hold a live investor conference call and webcast at 5:00pm Eastern/2:00pm Pacific.
Biotechnology Stocks Technical Review -- Research on Medivation, Idenix Pharma, Nanosphere, and Progenics Pharma
PR Newswire - Fri Jul 11, 7:00AM CDT
On Thursday, July 10, 2014, the NASDAQ Composite ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished the session at 16,915.07, down 0.42% and the S&P 500 closed at 1,964.68, down 0.41%. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.02% lower at 711.88, while the index has gained 9.23% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Nanosphere Inc. (NASDAQ: NSPH) and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). Free technical research on MDVN, IDIX, NSPH and PGNX can be downloaded upon signing up at:
Analysis of Global Biochips Industry, 2012-2018
M2 - Wed Jul 09, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf67jr/analysis_of) has announced the addition of the "Analysis of Global Biochips Industry, 2012-2018" report to their offering. Global biochips market is forecasted to reach US$11.4 billion by 2018 with a CAGR of 18.6% during 2012-2018; the massive CAGR is primarily supported by Asia-Pacific followed by the European Union. Among the major industry segments, biochips instruments are expected to exert the highest support to the industry with a CAGR of 20% globally. Microarrays segment accounts for nearly 70% of the industry value while services indicate lesser than 15% of the market value. North America is expected to maintain the highest market share for the biochips industry by 2018; Asian economies are expected to post a large CAGR of 19 percent during 2012-2018. Higher growth rate favors improved industry investments in Asia-Pacific region in comparison with North America and Europe, going ahead. Report Focus: The report Analysis of Global Biochips Industry, 2012-2018' reviews the latest biochips market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations. The report primarily focuses on: Companies Mentioned: - Affymetrix, Inc. - Agilent Technologies - Arkray, Inc. - Biobase - Biodot, Inc. - Biofluidix Gmbh - Biom?rieux Sa - Cellix Limited - Compugen - Courtagen Life Sciences, Inc. - Cytopathfinder, Inc. - Dr. Chip Biotechnology Inc. - Epigem Ltd. - Immunexpress Pty Ltd - Lavision Biotec Gmbh - Lightarray Gene Technology Co., Ltd. - Med Biogene Inc. - Microarrays, Inc. - Micronit Microfluidics Bv - Miltenyi Biotec - Mitsubishi Rayon Co., Ltd. - Nanosphere, Inc. - Nanostring? Technologies, Inc. - Promega Corporation - Protagen Ag - Strand Life Sciences - Ttp Labtech Ltd - Vance Street Capital Llc - Varionostic Gmbh - Zeptosens Ag For more information visit http://www.researchandmarkets.com/research/zf...nalysis_of
Stock to Watch: Nanosphere Down 5.2% (NSPH)
Comtex SmarTrend(R) - Thu Jun 26, 11:39AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's worst performing low-priced stocks, down 5.2% to $1.57 on 1.1x average daily volume. Nanosphere has traded 965,000 shares thus far today, vs. average volume of 856,000 shares per day. The stock has underperformed the Dow (-5.2% to the Dow's -0.5%) and underperformed the S&P 500 (-5.2% to the S&P's -0.4%) during today's trading.
New Patents, Clinical Trial Updates, New Agreements, and FDA Approvals - Analyst Notes on Agile Therapeutics, Vanda, Galena, Nanosphere and Rockwell
PR Newswire - Thu Jun 26, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Agile Therapeutics, Inc. (NASDAQ: AGRX), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Galena Biopharma, Inc. (NASDAQ: GALE), Nanosphere, Inc. (NASDAQ: NSPH) and Rockwell Medical Technologies Inc. (NASDAQ: RMTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4128-100free.
Why Nanosphere (NSPH) Stock Is Surging Today
at The Street - Wed Jun 25, 1:13PM CDT
Nanosphere (NSPH) surged Wednesday after the molecular diagnostics company announced it has received FDA clearance for the bacterial portion of its Verigene Enteric Pathogens Nucleic Acid Test.
Stock to Watch: Nanosphere Up 5.9% (NSPH)
Comtex SmarTrend(R) - Mon Sep 08, 10:38AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's best performing penny stocks, up 5.9% to $0.59 on 2.8x average daily volume. Nanosphere has traded 2.3 million shares thus far today, vs. average volume of 803,000 shares per day. The stock has outperformed the Dow (5.9% to the Dow's -0.1%) and outperformed the S&P 500 (5.9% to the S&P's -0.1%) during today's trading.
New Outcomes Data Presented at ICAAC 2014 Further Validates Clinical and Economic Utility of Nanosphere's Verigene Blood Culture Test
GlobeNewswire - Mon Sep 08, 7:06AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, announced that data from three outcomes studies demonstrating the clinical and economic impact of the Verigene(R) Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) for rapid sepsis diagnostic testing were presented yesterday at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in Washington, DC this week.
Nanosphere (NSPH) Slumps: NSPH Plunges 14.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:33AM CDT
Nanosphere, Inc. (NSPH) saw a big move last session,continuing the recent downtrend for NSPH, as the stock is now down 54.2% in the past one-month time frame.
VXZ, SPPRO, DLA, NSPH, USL, TITN Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Sep 05, 3:35AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of IPATH S&P 500 VIX M/T FU ETN (NYSE:VXZ), Supertel Hospitality Inc (NASDAQ:SPPRO), Delta Apparel Inc (NYSE
LA), Nanosphere Inc (NASDAQ:NSPH), United States 12 Month Oil Fund LP (NYSE:USL), Titan Machinery Inc (NASDAQ:TITN) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: Nanosphere Announces Review of Strategic Alternatives
GlobeNewswire - Thu Sep 04, 3:01PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that the Company has engaged Jefferies LLC as its financial advisor to assist it in the development and evaluation of a full range of potential strategic alternatives for the Company.
Investors look to Lighten Up on Shares of Nanosphere, Shares Down 9.2% (NSPH)
Comtex SmarTrend(R) - Thu Sep 04, 10:38AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's worst performing penny stocks, down 9.2% to $0.69 on 1.3x average daily volume. Thus far today, Nanosphere has traded 912,000 shares, vs. average volume of 715,000 shares per day. The stock has underperformed the Dow (-8.8% to the Dow's 0.3%) and underperformed the S&P 500 (-8.8% to the S&P's 0.3%) during today's trading.
New Clinical and Economic Outcome Data for Verigene Blood Culture Test to Be Presented at ICAAC 2014
GlobeNewswire - Tue Sep 02, 7:00AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that three outcomes studies demonstrating the clinical and economic impact of the Verigene(R) Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) will be presented at the 54 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held in Washington, DC on September 5 - 9, 2014.
Nanosphere Appoints Kristopher Wood to Its Board of Directors
GlobeNewswire - Wed Aug 20, 3:01PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced the appointment of Kristopher Wood to its board of directors. Mr. Wood brings to Nanosphere extensive experience in finance, strategy and venture capital.
Expert Briefing on Biotech Stocks -- Nanosphere, Vanda Pharma, Synta Pharma, Halozyme Therapeutics, and Isis Pharma
PR Newswire - Thu Aug 14, 8:30AM CDT
On Wednesday, August 13, 2014, the NASDAQ Composite ended at 4,434.13, up 1.02%, the Dow Jones Industrial Average finished the day 0.55% higher at 16,651.80, and the S&P 500 closed at 1,946.72, up 0.67%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.08, up 1.15%, with the index also advancing 4.55% in the previous three months. Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at:
Downgrade Alert for Nanosphere (NSPH)
Comtex SmarTrend(R) - Fri Aug 08, 7:08AM CDT
Nanosphere (NASDAQ:NSPH) was downgraded from Buy to Hold at Craig-Hallum today. The stock closed yesterday at $0.95 on volume of 4.9 million shares, above average daily volume of 1.2 million. Nanosphere Inc. develops, manufactures and markets an advanced molecular diagnostics platform. The Company's system allows highly sensitive genomic and protein testing on a single platform.
Why Nanosphere (NSPH) Stock Hit a One-Year Low Today
at The Street - Thu Aug 07, 12:12PM CDT
Nanosphere (NSPH) plummeted to a 52-week low of 92 cents on Thursday after the company reported second-quarter earnings and issued full-year revenue guidance that came up short of analysts' expectations.
Stock to Watch: Nanosphere Down 30.3% (NSPH)
Comtex SmarTrend(R) - Thu Aug 07, 10:11AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's worst performing penny stocks, down 30.3% to $0.99 on 1.8x average daily volume. Nanosphere has traded 2.6 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has underperformed the Dow (-30.3% to the Dow's -0.0%) and underperformed the S&P 500 (-30.3% to the S&P's 0.0%) during today's trading.
Nanosphere Announces Second Quarter Financial and Operating Results
GlobeNewswire - Wed Aug 06, 3:03PM CDT
Corporate Highlights and Business Guidance:
HemoSonics Names William P. Moffitt as Chairman of the Board of Managers
PR Newswire - Thu Jul 31, 9:23AM CDT
HemoSonics, a medical device company developing a novel point-of-care diagnostic to measure coagulation, announced today that William P. (Bill) Moffitt joined the Company as the new Chairman of the Board of Managers. Moffitt has 40 years of experience in the medical device and diagnostic industries and has spent the last 25 years developing novel technologies into products and solutions that have helped shape the industry.
Nanosphere to Release Second Quarter Results and Host Investor Conference Call on Wednesday, August 6, 2014
GlobeNewswire - Wed Jul 23, 7:26AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it will report its results for the second quarter of 2014 on Wednesday, August 6, 2014. The company will also hold a live investor conference call and webcast at 5:00pm Eastern/2:00pm Pacific.
Biotechnology Stocks Technical Review -- Research on Medivation, Idenix Pharma, Nanosphere, and Progenics Pharma
PR Newswire - Fri Jul 11, 7:00AM CDT
On Thursday, July 10, 2014, the NASDAQ Composite ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished the session at 16,915.07, down 0.42% and the S&P 500 closed at 1,964.68, down 0.41%. During the trading session, eight out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.02% lower at 711.88, while the index has gained 9.23% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Nanosphere Inc. (NASDAQ: NSPH) and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX). Free technical research on MDVN, IDIX, NSPH and PGNX can be downloaded upon signing up at:
Analysis of Global Biochips Industry, 2012-2018
M2 - Wed Jul 09, 2:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zf67jr/analysis_of) has announced the addition of the "Analysis of Global Biochips Industry, 2012-2018" report to their offering. Global biochips market is forecasted to reach US$11.4 billion by 2018 with a CAGR of 18.6% during 2012-2018; the massive CAGR is primarily supported by Asia-Pacific followed by the European Union. Among the major industry segments, biochips instruments are expected to exert the highest support to the industry with a CAGR of 20% globally. Microarrays segment accounts for nearly 70% of the industry value while services indicate lesser than 15% of the market value. North America is expected to maintain the highest market share for the biochips industry by 2018; Asian economies are expected to post a large CAGR of 19 percent during 2012-2018. Higher growth rate favors improved industry investments in Asia-Pacific region in comparison with North America and Europe, going ahead. Report Focus: The report Analysis of Global Biochips Industry, 2012-2018' reviews the latest biochips market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations. The report primarily focuses on: Companies Mentioned: - Affymetrix, Inc. - Agilent Technologies - Arkray, Inc. - Biobase - Biodot, Inc. - Biofluidix Gmbh - Biom?rieux Sa - Cellix Limited - Compugen - Courtagen Life Sciences, Inc. - Cytopathfinder, Inc. - Dr. Chip Biotechnology Inc. - Epigem Ltd. - Immunexpress Pty Ltd - Lavision Biotec Gmbh - Lightarray Gene Technology Co., Ltd. - Med Biogene Inc. - Microarrays, Inc. - Micronit Microfluidics Bv - Miltenyi Biotec - Mitsubishi Rayon Co., Ltd. - Nanosphere, Inc. - Nanostring? Technologies, Inc. - Promega Corporation - Protagen Ag - Strand Life Sciences - Ttp Labtech Ltd - Vance Street Capital Llc - Varionostic Gmbh - Zeptosens Ag For more information visit http://www.researchandmarkets.com/research/zf...nalysis_of
Stock to Watch: Nanosphere Down 5.2% (NSPH)
Comtex SmarTrend(R) - Thu Jun 26, 11:39AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's worst performing low-priced stocks, down 5.2% to $1.57 on 1.1x average daily volume. Nanosphere has traded 965,000 shares thus far today, vs. average volume of 856,000 shares per day. The stock has underperformed the Dow (-5.2% to the Dow's -0.5%) and underperformed the S&P 500 (-5.2% to the S&P's -0.4%) during today's trading.
New Patents, Clinical Trial Updates, New Agreements, and FDA Approvals - Analyst Notes on Agile Therapeutics, Vanda, Galena, Nanosphere and Rockwell
PR Newswire - Thu Jun 26, 4:10AM CDT
Today, Analysts Review released its analysts' notes regarding Agile Therapeutics, Inc. (NASDAQ: AGRX), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Galena Biopharma, Inc. (NASDAQ: GALE), Nanosphere, Inc. (NASDAQ: NSPH) and Rockwell Medical Technologies Inc. (NASDAQ: RMTI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4128-100free.
Why Nanosphere (NSPH) Stock Is Surging Today
at The Street - Wed Jun 25, 1:13PM CDT
Nanosphere (NSPH) surged Wednesday after the molecular diagnostics company announced it has received FDA clearance for the bacterial portion of its Verigene Enteric Pathogens Nucleic Acid Test.
